Shares of Assembly Biosciences, Inc. (NASDAQ: ASMB) plummeted 69.37% on Friday. The drop in stock prices came after it disclosed the discouraging result from a Phase 2 study analyzing vebicorvir (VBR) in treating patients with chronic hepatitis B virus (HBV) infection. The
